PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
Nov 1, 2004, 00:00
10.1016/S1098-3015(10)65736-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)65736-1/fulltext
Title :
PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65736-1&doi=10.1016/S1098-3015(10)65736-1
First page :
Section Title :
Open access? :
No
Section Order :
103